Five pricings pushed 2013 ahead of 2012's full-year US IPO total last week. The year's 130 US IPOs (vs. 128 in all of 2012) are the second-most through August since 2000. At the same time, with nine new filers, 2013 also surpassed 2012's full-year total for...read more
Sophiris Bio, which is developing a biologic to treat enlarged prostates, raised $65 million by offering 13.0 million shares at $5. The company had previously filed to offer 5.0 million shares at $13. Sophiris Bio plans to list on the NASDAQ under the symbol...read more
Sophiris Bio, which is developing a biologic to treat enlarged prostates, lowered its proposed IPO price on Thursday. The La Jolla, CA-based company now plans to raise $65 million by offering 13.0 million shares at a price of $5. The company had previously filed...read more
US IPO Recap: 2013 breaks past 2012's IPO totals in pricings and filings
Five pricings pushed 2013 ahead of 2012's full-year US IPO total last week. The year's 130 US IPOs (vs. 128 in all of 2012) are the second-most through August since 2000. At the same time, with nine new filers, 2013 also surpassed 2012's full-year total for...read more
Sophiris Bio prices IPO at $5, below expectations
Sophiris Bio, which is developing a biologic to treat enlarged prostates, raised $65 million by offering 13.0 million shares at $5. The company had previously filed to offer 5.0 million shares at $13. Sophiris Bio plans to list on the NASDAQ under the symbol...read more
Sophiris Bio decreases proposed IPO price
Sophiris Bio, which is developing a biologic to treat enlarged prostates, lowered its proposed IPO price on Thursday. The La Jolla, CA-based company now plans to raise $65 million by offering 13.0 million shares at a price of $5. The company had previously filed...read more
5 US IPOs planned for the week of Aug 12
The following IPOs are expected to price this week: China Commercial Credit (CCCR), a microcredit lender to small businesses in the Jiangsu Province of China, plans to...read more